ClinicalTrials.gg
RecruitingNCT06837181SPeCTRuMUpdated Feb 10, 2026

Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)

An observational study in Cystic Fibrosis (CF), Cystic Fibrosis-related Diabetes and Diabetes, sponsored by Jaeb Center for Health Research. Recruiting at 18 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by Jaeb Center for Health Research · Observational

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
200
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 717 studies in Cystic Fibrosis with a site in United States — 85 open to participants now, 111 under way, 8 of them phase 3. Cystic Fibrosis · United States.

Planned enrollment
52nd of 193
200 · median 80
Started
2025
with 19 others
Observational
194 of 717
41 open now
Primary completion
2028-11
later than 91 of 108 live
Registered
686th of 717
by date

Among the 717 studies in Cystic Fibrosis with a site in United States, this one is the 52nd largest by planned enrollment of the 193 observational ones that give a count, is one of 20 that started in 2025, is one of 194 observational ones, reaches primary completion later than 91 of the 108 other live ones, and was the 686th registered.

Cystic Fibrosis

1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

85 of the 717 studies in Cystic Fibrosis with a site in United States are open now. Recruiting first, the newest first:

79 more — sign in →

All 85 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 717 studies in Cystic Fibrosis with a site in United States, or all of them as a file.
02

Study summary

This multicenter cross-sectional study will include a diverse population of adolescents and adults with CF.

The overall Aim is to describe prevalence of diabetes microvascular complications and macrovascular surrogates in people with established CFRD.

03

Conditions studied

  • Cystic Fibrosis (CF)
  • Cystic Fibrosis-related Diabetes
  • Diabetes
  • Retinopathy
  • Neuropathy
  • Nephropathy
  • Blood Pressure
  • Cardiovascular Risk
  • Microvascular

Keywords

  • Cystic Fibrosis
  • CFRD
  • Cystic Fibrosis-Related Diabetes
  • Observational
  • Physical Activity Tracker
  • Continuous glucose monitoring
  • CGM
  • Diabetes
  • blood pressure
  • cardiovascular risk
  • microvascular
  • diabetes complications
  • social determinants of health
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals with CFRD diagnosis ≥ 5 years at time of enrollment

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written (and assent when applicable) obtained from participant or participant's legally authorized representative
  • For Adults: Must be able to consent on one own's behalf (i.e., cannot lack cognitive capacity to consent due to the required patient-reported outcomes)
  • Be willing and able to adhere to the study protocol requirements
  • Age ≥ 12 years at time of enrollment
  • CF diagnosis based on two CF causing mutations and/or positive sweat test according to CFF diagnostic criteria
  • CFRD diagnosis ≥ 5 years at time of enrollment

Exclusion criteria

Exclusion Criteria:

  • History of any illness or condition that, in the opinion of the investigator might confound the results of the study or pose an additional risk to the subject
  • History of transplant
  • Pregnancy reported by participant at time of consent or at any point during active study participation

Pulse Wave Velocity Exclusion Criteria:

  • Erratic, accelerated or mechanically controlled irregular heart rhythms including arrhythmias
  • Carotid or aortic valve stenosis
  • Peripheral artery disease or leg artery disease
  • Generalized constriction or localized spasm of muscular conduit arteries such as seen immediately after hypothermic cardiopulmonary bypass surgery or accompanying Raynaud's phenomena or intense cold.
  • Possible exclusions based on investigator medical provider assessment (additional precautions may be followed to allow inclusion):

    • Pressure reading should not be conducted on a limb where there is intravenous access, arterio-venous shunt, or where circulation is compromised.
    • Pressure reading should not be conducted on the side of the body that a mastectomy was done.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
200 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Individuals with Cystic Fibrosis-Related Diabetes

    Individuals diagnosed with Cystic Fibrosis-Related Diabetes for more than 5 years before enrollment

    Other: observational study

Interventions

  • Otherobservational study

    This is an observational study.

06

What researchers measure

Primary outcomes

  1. Microvascular Complications

    To describe the rates of microvascular complications (retinopathy, nephropathy, and peripheral neuropathy) and their relationships with HbA1c and diabetes duration in diverse cohort of adolescents and adults with CFRD for ≥5 years.

    Time frame: From enrollment to the end of the participant's participation or 4 weeks

  2. Macrovascular Surrogates

    To describe macrovascular surrogates (resting blood pressure (BP), fasting lipids) and their relationship with HbA1c, diabetes duration and BMI in a diverse cohort with established CFRD.

    Time frame: From enrollment to the end of the participant's participation or 4 weeks

Secondary outcomes

  1. PhenX English Proficiency

    This questionnaire will be used to describe the social determinants of health in the study population and their cross-sectional relationships with microvascular complications and macrovascular surrogates will largely be explored.

    Time frame: From enrollment to the end of the participant's participation or 4 weeks

  2. PhenX Food Security & Prescription Accessibility

    This questionnaire will be used to describe the social determinants of health in the study population and their cross-sectional relationships with microvascular complications and macrovascular surrogates will largely be explored.

    Time frame: From enrollment to the end of the participant's participation or 4 weeks

  3. Exercise and Substance Use

    This questionnaire ask questions regarding participants' physical activity, sleeping habits and substance use.

    Time frame: From enrollment to the end of the participant's participation or 4 weeks

  4. Pubertal Self-Assessment

    A self-evaluation questionnaire to assess child's pubertal development.

    Time frame: From enrollment to the end of the participant's participation or 4 weeks

  5. Beverage Questionnaire (BEVQ15)

    A questionnaire that asks the frequency and amount of beverage intake for the past month.

    Time frame: From enrollment to the end of the participant's participation or 4 weeks

  6. CFRD Care & Technology

    This is a questionnaire that asks participants regarding their CFRD care and the technology they use to help them manage diabetes.

    Time frame: From enrollment to the end of the participant's participation or 4 weeks

  7. Diabetes Management Experience

    This is a questionnaire that asks how participants manage their diabetes for the past 12 months.

    Time frame: From enrollment to the end of the participant's participation or 4 weeks

  8. Problem Areas in Diabetes (PAID)

    Questionnaire that asks participants about possible diabetes-related issues they have experienced.

    Time frame: From enrollment to the end of the participant's participation or 4 weeks

  9. Problem Areas in Diabetes Parents of Teens (P-PAID-T)

    Questionnaire about what the parent or guardian of a participant may experience with their child's diabetes and rating how true it is for them over the past month.

    Time frame: From enrollment to the end of the participant's participation or 4 weeks

  10. Hypoglycemia Fear Survey (Child)

    A survey that consists of 25 questions and selecting from scale (0 = never to 4 = always) about how low blood sugar makes children feel and do.

    Time frame: From enrollment to the end of the participant's participation or 4 weeks

  11. Hypoglycemia Fear Survey (Parent)

    Survey that consists of 25 questions about the frequency of things parents of children with diabetes sometimes do to keep from having low blood sugar.

    Time frame: From enrollment to the end of the participant's participation or 4 weeks

  12. Hypoglycemia Fear Survey (Adult-Short Form)/Worry (HFS-II-Worry)

    A survey about various scenarios that may happen to the participant and rating how true it is for them over the past 6 months.

    Time frame: From enrollment to the end of the participant's participation or 4 weeks

  13. Gold Score

    A 7 item scale that measures hypoglycemia awareness

    Time frame: From enrollment to the end of the participant's participation or 4 weeks

  14. All of Us

    A questionnaire that consists of 14 questions asking about the participant, their work and their home life.

    Time frame: From enrollment to the end of the participant's participation or 4 weeks

  15. Continuous glucose monitoring (CGM)-defined glycemic control (time-in-range, time-above-range, time-below-range, glucose variability), and the relationships between CGM metrics and HbA1c, in a diverse population of people with established CFRD

    This will be measured using a continuous glucose monitor that will be worn by the participant for 3 to 10 days.

    Time frame: 3-10 days

  16. Diversity of participants enrolled and barriers to enrollment

    This will be measured using the patient-related outcomes questionnaires.

    Time frame: From enrollment to the end of the participant's participation or 4 weeks

  17. Renal function by eGFR

    Function will be assessed by collection of creatinine and Cystatin-C

    Time frame: From enrollment to the end of the participant's participation or 4 weeks

  18. Liver function

    This will be measured by liver enzymes and complete blood count (CBC); APRI and EMR data for liver imaging

    Time frame: From enrollment to the end of the participant's participation or 4 weeks

Other outcomes

  1. Exploratory Outcome - Participant diversity

    This will measure diversity of individuals who were approached for study inclusion, who were recruited, who consented and who partially or fully completed study procedures as well as barriers and facilitators to recruitment.

    Time frame: From enrollment to the end of the participant's participation or 4 weeks

  2. Cardiovascular sub-study - Pulse Wave Velocity and Pulse Wave Analysis (PWV & PWA)

    A Sphygmocor XCEL device will be used to measure PWV/PWA (m/sec), pulse pressure amplification and augmentation index (Aix) and Aix adjusted to a HR of 75 (Aix-75).

    Time frame: 1 study visit day

  3. Exploratory Outcome - HbA1c and CGM metrics with nutritional intake

    The participant will complete 3-day recall of food intake using NIH's Automated Self-Administered 24-Hour (ASA24) Dietary Assessment Tool.

    Time frame: 3 days

  4. Exploratory Outcome - HbA1c and CGM metrics with physical activity

    The participant will be required to wear an accelerometer device for 3 to 10 days to assess physical activity.

    Time frame: 3-10 days

  5. Cardiovascular sub-study - Ambulatory Blood Pressure Monitoring

    An oscillometric Spacelab monitors will be used to measure variables including SBP/DBP and BP load (%BP above 95th percentile for sex and height) for the 24-hour period and awake/sleep period. Sleep time will be determined from actigraphy and participant documentation.

    Time frame: 24 hours

  6. Fecal Collection

    Participant stool sample will be obtained for fecal elastase only for those for pancreatic sufficiency status is unclear.

    Time frame: From enrollment to the end of the participant's participation or 4 weeks

  7. Sample Collection for Biorepository

    Blood, urine and stool will be collected for biorepository.

    Time frame: From enrollment to the end of the participant's participation or 4 weeks

  8. Information Collection for Geocoding

    The study will use the participants' addresses or part of their addresses (such as their zip codes) to allow researchers to look at how where they live might be related to their health through geocoding.

    Time frame: from enrollment

07

Study locations

5 of 18 sites recruiting
08

References and documents

Publications

  • Agbaje AO, Barker AR, Tuomainen TP. Differing Relations Of Arterial Stiffness And Carotid Intima-Media Thickness In Adolescence With Metabolic Risks In Young Adulthood: The ALSPAC Study. Circulation. 2021;144(Suppl_1):A13236-A. doi: doi:10.1161/circ.144.suppl_1.13236
  • Kelly A, Magge SN, Walega R, Cochrane C, Pipan ME, Zemel BS, Cohen MS, Gidding SS, Townsend R. Cross-Sectional Study of Arterial Stiffness in Adolescents with Down Syndrome. J Pediatr. 2019 Sep;212:79-86.e1. doi: 10.1016/j.jpeds.2019.04.059. Epub 2019 Jun 11. PubMed 31201031 ↗
  • DeLoach SS, Townsend RR. Vascular stiffness: its measurement and significance for epidemiologic and outcome studies. Clin J Am Soc Nephrol. 2008 Jan;3(1):184-92. doi: 10.2215/CJN.03340807. PubMed 18178784 ↗
  • Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994 Nov;17(11):1281-9. doi: 10.2337/diacare.17.11.1281. PubMed 7821168 ↗
  • Bergman M, Tuomilehto J. International Diabetes Federation Position Statement on the 1-hour post-load plasma glucose for the diagnosis of intermediate hyperglycaemia and type 2 diabetes. Diabetes Res Clin Pract. 2024 Apr;210:111636. doi: 10.1016/j.diabres.2024.111636. Epub 2024 Mar 25. No abstract available. PubMed 38537890 ↗
  • Bergman M, Manco M, Satman I, Chan J, Schmidt MI, Sesti G, Vanessa Fiorentino T, Abdul-Ghani M, Jagannathan R, Kumar Thyparambil Aravindakshan P, Gabriel R, Mohan V, Buysschaert M, Bennakhi A, Pascal Kengne A, Dorcely B, Nilsson PM, Tuomi T, Battelino T, Hussain A, Ceriello A, Tuomilehto J. International Diabetes Federation Position Statement on the 1-hour post-load plasma glucose for the diagnosis of intermediate hyperglycaemia and type 2 diabetes. Diabetes Res Clin Pract. 2024 Mar;209:111589. doi: 10.1016/j.diabres.2024.111589. Epub 2024 Mar 7. PubMed 38458916 ↗
  • McGarry M. Transparency and diversity in cystic fibrosis research. Lancet. 2020 Aug 29;396(10251):601. doi: 10.1016/S0140-6736(20)30906-5. No abstract available. PubMed 32861304 ↗
  • Kartal Ozturk G, Conkar S, Eski A, Gulen F, Keskinoglu A, Demir E. Evaluation of increased arterial stiffness in pediatric patients with cystic fibrosis by augmentation index and pulse wave velocity analysis. Pediatr Pulmonol. 2020 May;55(5):1147-1153. doi: 10.1002/ppul.24688. Epub 2020 Feb 14. PubMed 32057197 ↗
  • Eising JB, van der Ent CK, Teske AJ, Vanderschuren MM, Uiterwaal CSPM, Meijboom FJ. Young patients with cystic fibrosis demonstrate subtle alterations of the cardiovascular system. J Cyst Fibros. 2018 Sep;17(5):643-649. doi: 10.1016/j.jcf.2017.12.009. Epub 2018 Feb 3. PubMed 29398489 ↗
  • Buehler T, Steinmann M, Singer F, Regamey N, Casaulta C, Schoeni MH, Simonetti GD. Increased arterial stiffness in children with cystic fibrosis. Eur Respir J. 2012 Jun;39(6):1536-7. doi: 10.1183/09031936.00212511. No abstract available. PubMed 22654008 ↗
  • Urbina EM, Isom S, Bell RA, Bowlby DA, D'Agostino R Jr, Daniels SR, Dolan LM, Imperatore G, Marcovina SM, Merchant AT, Reynolds K, Shah AS, Wadwa RP, Dabelea D; SEARCH for Diabetes in Youth Study Group. Burden of Cardiovascular Risk Factors Over Time and Arterial Stiffness in Youth With Type 1 Diabetes Mellitus: The SEARCH for Diabetes in Youth Study. J Am Heart Assoc. 2019 Jul 2;8(13):e010150. doi: 10.1161/JAHA.118.010150. Epub 2019 Jun 19. PubMed 31213111 ↗
  • Stoner L, Kucharska-Newton A, Meyer ML. Cardiometabolic Health and Carotid-Femoral Pulse Wave Velocity in Children: A Systematic Review and Meta-Regression. J Pediatr. 2020 Mar;218:98-105.e3. doi: 10.1016/j.jpeds.2019.10.065. Epub 2019 Dec 4. PubMed 31810627 ↗
  • Reference Values for Arterial Stiffness' Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: 'establishing normal and reference values'. Eur Heart J. 2010 Oct;31(19):2338-50. doi: 10.1093/eurheartj/ehq165. Epub 2010 Jun 7. PubMed 20530030 ↗
  • Mendizabal B, Urbina EM. Subclinical Atherosclerosis in Youth: Relation to Obesity, Insulin Resistance, and Polycystic Ovary Syndrome. J Pediatr. 2017 Nov;190:14-20. doi: 10.1016/j.jpeds.2017.06.043. Epub 2017 Jul 13. No abstract available. PubMed 28712518 ↗
  • Khoury M, Urbina EM. Hypertension in adolescents: diagnosis, treatment, and implications. Lancet Child Adolesc Health. 2021 May;5(5):357-366. doi: 10.1016/S2352-4642(20)30344-8. Epub 2021 Mar 10. PubMed 33711291 ↗
  • Cote AT, Phillips AA, Harris KC, Sandor GG, Panagiotopoulos C, Devlin AM. Obesity and arterial stiffness in children: systematic review and meta-analysis. Arterioscler Thromb Vasc Biol. 2015 Apr;35(4):1038-44. doi: 10.1161/ATVBAHA.114.305062. Epub 2015 Jan 29. PubMed 25633314 ↗
  • Agbaje AO, Barker AR, Tuomainen TP. Effects of Arterial Stiffness and Carotid Intima-Media Thickness Progression on the Risk of Overweight/Obesity and Elevated Blood Pressure/Hypertension: a Cross-Lagged Cohort Study. Hypertension. 2022 Jan;79(1):159-169. doi: 10.1161/HYPERTENSIONAHA.121.18449. Epub 2021 Nov 17. PubMed 34784721 ↗
  • Agbaje AO, Barker AR, Tuomainen TP. Cardiorespiratory Fitness, Fat Mass, and Cardiometabolic Health with Endothelial Function, Arterial Elasticity, and Stiffness. Med Sci Sports Exerc. 2022 Jan 1;54(1):141-152. doi: 10.1249/MSS.0000000000002757. PubMed 34334718 ↗
  • Agbaje AO, Barker AR, Mitchell GF, Tuomainen TP. Effect of Arterial Stiffness and Carotid Intima-Media Thickness Progression on the Risk of Dysglycemia, Insulin Resistance, and Dyslipidemia: a Temporal Causal Longitudinal Study. Hypertension. 2022 Mar;79(3):667-678. doi: 10.1161/HYPERTENSIONAHA.121.18754. Epub 2022 Jan 18. PubMed 35038890 ↗
  • Townsend RR, Wilkinson IB, Schiffrin EL, Avolio AP, Chirinos JA, Cockcroft JR, Heffernan KS, Lakatta EG, McEniery CM, Mitchell GF, Najjar SS, Nichols WW, Urbina EM, Weber T; American Heart Association Council on Hypertension. Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness: A Scientific Statement From the American Heart Association. Hypertension. 2015 Sep;66(3):698-722. doi: 10.1161/HYP.0000000000000033. Epub 2015 Jul 9. No abstract available. PubMed 26160955 ↗
  • Mitchell GF. Arterial Stiffness in Aging: Does It Have a Place in Clinical Practice?: Recent Advances in Hypertension. Hypertension. 2021 Mar 3;77(3):768-780. doi: 10.1161/HYPERTENSIONAHA.120.14515. Epub 2021 Feb 1. PubMed 33517682 ↗
  • Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H; European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006 Nov;27(21):2588-605. doi: 10.1093/eurheartj/ehl254. Epub 2006 Sep 25. PubMed 17000623 ↗
  • Chirinos JA, Segers P, Hughes T, Townsend R. Large-Artery Stiffness in Health and Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019 Sep 3;74(9):1237-1263. doi: 10.1016/j.jacc.2019.07.012. PubMed 31466622 ↗
  • Boutouyrie P, Chowienczyk P, Humphrey JD, Mitchell GF. Arterial Stiffness and Cardiovascular Risk in Hypertension. Circ Res. 2021 Apr 2;128(7):864-886. doi: 10.1161/CIRCRESAHA.121.318061. Epub 2021 Apr 1. PubMed 33793325 ↗
  • Karnsakul W, Wasuwanich P, Ingviya T, Vasilescu A, Carson KA, Mogayzel PJ, Schwarz KB. A longitudinal assessment of non-invasive biomarkers to diagnose and predict cystic fibrosis-associated liver disease. J Cyst Fibros. 2020 Jul;19(4):546-552. doi: 10.1016/j.jcf.2020.05.002. Epub 2020 May 30. PubMed 32482593 ↗
  • Ayoub F, Trillo-Alvarez C, Morelli G, Lascano J. Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease. World J Hepatol. 2018 Jan 27;10(1):34-40. doi: 10.4254/wjh.v10.i1.34. PubMed 29399276 ↗
  • Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020 May;158(7):1999-2014.e1. doi: 10.1053/j.gastro.2019.11.312. Epub 2020 Feb 8. PubMed 32044314 ↗
  • Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018 Jun;71(6):e13-e115. doi: 10.1161/HYP.0000000000000065. Epub 2017 Nov 13. No abstract available. PubMed 29133356 ↗
  • Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, Boehme AK, Buxton AE, Carson AP, Commodore-Mensah Y, Elkind MSV, Evenson KR, Eze-Nliam C, Ferguson JF, Generoso G, Ho JE, Kalani R, Khan SS, Kissela BM, Knutson KL, Levine DA, Lewis TT, Liu J, Loop MS, Ma J, Mussolino ME, Navaneethan SD, Perak AM, Poudel R, Rezk-Hanna M, Roth GA, Schroeder EB, Shah SH, Thacker EL, VanWagner LB, Virani SS, Voecks JH, Wang NY, Yaffe K, Martin SS. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation. 2022 Feb 22;145(8):e153-e639. doi: 10.1161/CIR.0000000000001052. Epub 2022 Jan 26. PubMed 35078371 ↗
  • Khosla L, Bhat S, Fullington LA, Horlyck-Romanovsky MF. HbA1c Performance in African Descent Populations in the United States With Normal Glucose Tolerance, Prediabetes, or Diabetes: A Scoping Review. Prev Chronic Dis. 2021 Mar 11;18:E22. doi: 10.5888/pcd18.200365. PubMed 33705304 ↗
  • Herman WH. Are There Clinical Implications of Racial Differences in HbA1c? Yes, to Not Consider Can Do Great Harm! Diabetes Care. 2016 Aug;39(8):1458-61. doi: 10.2337/dc15-2686. PubMed 27457636 ↗
  • Yapanis M, James S, Craig ME, O'Neal D, Ekinci EI. Complications of Diabetes and Metrics of Glycemic Management Derived From Continuous Glucose Monitoring. J Clin Endocrinol Metab. 2022 May 17;107(6):e2221-e2236. doi: 10.1210/clinem/dgac034. PubMed 35094087 ↗
  • Xu Y, Bergenstal RM, Dunn TC, Ram Y, Ajjan RA. Interindividual variability in average glucose-glycated haemoglobin relationship in type 1 diabetes and implications for clinical practice. Diabetes Obes Metab. 2022 Sep;24(9):1779-1787. doi: 10.1111/dom.14763. Epub 2022 Jun 2. PubMed 35546274 ↗
  • Scully KJ, Sherwood JS, Martin K, Ruazol M, Marchetti P, Larkin M, Zheng H, Sawicki GS, Uluer A, Neuringer I, Yonker LM, Sicilian L, Wexler DJ, Putman MS. Continuous Glucose Monitoring and HbA1c in Cystic Fibrosis: Clinical Correlations and Implications for CFRD Diagnosis. J Clin Endocrinol Metab. 2022 Mar 24;107(4):e1444-e1454. doi: 10.1210/clinem/dgab857. PubMed 34850006 ↗
  • Chan CL, Steck AK, Severn C, Pyle L, Rewers M, Zeitler PS. Lessons From Continuous Glucose Monitoring in Youth With Pre-Type 1 Diabetes, Obesity, and Cystic Fibrosis. Diabetes Care. 2020 Mar;43(3):e35-e37. doi: 10.2337/dc19-1690. Epub 2020 Jan 14. No abstract available. PubMed 31937609 ↗
  • Chan CL, Pyle L, Vigers T, Zeitler PS, Nadeau KJ. The Relationship Between Continuous Glucose Monitoring and OGTT in Youth and Young Adults With Cystic Fibrosis. J Clin Endocrinol Metab. 2022 Jan 18;107(2):e548-e560. doi: 10.1210/clinem/dgab692. PubMed 34537845 ↗
  • O'Riordan SM, Hindmarsh P, Hill NR, Matthews DR, George S, Greally P, Canny G, Slattery D, Murphy N, Roche E, Costigan C, Hoey H. Validation of continuous glucose monitoring in children and adolescents with cystic fibrosis: a prospective cohort study. Diabetes Care. 2009 Jun;32(6):1020-2. doi: 10.2337/dc08-1925. Epub 2009 Mar 11. PubMed 19279304 ↗
  • Shoemaker MJ, Hurt H, Arndt L. The evidence regarding exercise training in the management of cystic fibrosis: a systematic review. Cardiopulm Phys Ther J. 2008 Sep;19(3):75-83. PubMed 20467502 ↗
  • Dwyer TJ, Elkins MR, Bye PT. The role of exercise in maintaining health in cystic fibrosis. Curr Opin Pulm Med. 2011 Nov;17(6):455-60. doi: 10.1097/MCP.0b013e32834b6af4. PubMed 21881514 ↗
  • Beaudoin N, Bouvet GF, Coriati A, Rabasa-Lhoret R, Berthiaume Y. Combined Exercise Training Improves Glycemic Control in Adult with Cystic Fibrosis. Med Sci Sports Exerc. 2017 Feb;49(2):231-237. doi: 10.1249/MSS.0000000000001104. PubMed 27669451 ↗
  • Hamilton CM, Strader LC, Pratt JG, Maiese D, Hendershot T, Kwok RK, Hammond JA, Huggins W, Jackman D, Pan H, Nettles DS, Beaty TH, Farrer LA, Kraft P, Marazita ML, Ordovas JM, Pato CN, Spitz MR, Wagener D, Williams M, Junkins HA, Harlan WR, Ramos EM, Haines J. The PhenX Toolkit: get the most from your measures. Am J Epidemiol. 2011 Aug 1;174(3):253-60. doi: 10.1093/aje/kwr193. Epub 2011 Jul 11. PubMed 21749974 ↗
  • Petersen MC, Begnel L, Wallendorf M, Litvin M. Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis. J Cyst Fibros. 2022 Mar;21(2):265-271. doi: 10.1016/j.jcf.2021.11.012. Epub 2021 Dec 1. PubMed 34862121 ↗
  • Gary-Webb TL, Suglia SF, Tehranifar P. Social epidemiology of diabetes and associated conditions. Curr Diab Rep. 2013 Dec;13(6):850-9. doi: 10.1007/s11892-013-0427-3. PubMed 24085624 ↗
  • Hill-Briggs F, Adler NE, Berkowitz SA, Chin MH, Gary-Webb TL, Navas-Acien A, Thornton PL, Haire-Joshu D. Social Determinants of Health and Diabetes: A Scientific Review. Diabetes Care. 2020 Nov 2;44(1):258-79. doi: 10.2337/dci20-0053. Online ahead of print. No abstract available. PubMed 33139407 ↗
  • Haire-Joshu D, Hill-Briggs F. The Next Generation of Diabetes Translation: A Path to Health Equity. Annu Rev Public Health. 2019 Apr 1;40:391-410. doi: 10.1146/annurev-publhealth-040218-044158. Epub 2019 Jan 2. PubMed 30601723 ↗
  • Haw JS, Shah M, Turbow S, Egeolu M, Umpierrez G. Diabetes Complications in Racial and Ethnic Minority Populations in the USA. Curr Diab Rep. 2021 Jan 9;21(1):2. doi: 10.1007/s11892-020-01369-x. PubMed 33420878 ↗
  • Lado JJ, Lipman TH. Racial and Ethnic Disparities in the Incidence, Treatment, and Outcomes of Youth with Type 1 Diabetes. Endocrinol Metab Clin North Am. 2016 Jun;45(2):453-61. doi: 10.1016/j.ecl.2016.01.002. Epub 2016 Apr 7. PubMed 27241975 ↗
  • Walker AF, Schatz DA, Johnson C, Silverstein JH, Rohrs HJ. Disparities in social support systems for youths with type 1 diabetes. Clin Diabetes. 2015 Apr;33(2):62-9. doi: 10.2337/diaclin.33.2.62. PubMed 25897185 ↗
  • Centers for Disease Control and Prevention (CDC). Racial disparities in diabetes mortality among persons aged 1-19 years--United States, 1979-2004. MMWR Morb Mortal Wkly Rep. 2007 Nov 16;56(45):1184-7. PubMed 18004236 ↗
  • Willi SM, Miller KM, DiMeglio LA, Klingensmith GJ, Simmons JH, Tamborlane WV, Nadeau KJ, Kittelsrud JM, Huckfeldt P, Beck RW, Lipman TH; T1D Exchange Clinic Network. Racial-ethnic disparities in management and outcomes among children with type 1 diabetes. Pediatrics. 2015 Mar;135(3):424-34. doi: 10.1542/peds.2014-1774. PubMed 25687140 ↗
  • Valenzuela JM, Seid M, Waitzfelder B, Anderson AM, Beavers DP, Dabelea DM, Dolan LM, Imperatore G, Marcovina S, Reynolds K, Yi-Frazier J, Mayer-Davis EJ; SEARCH for Diabetes in Youth Study Group. Prevalence of and disparities in barriers to care experienced by youth with type 1 diabetes. J Pediatr. 2014 Jun;164(6):1369-75.e1. doi: 10.1016/j.jpeds.2014.01.035. Epub 2014 Feb 25. PubMed 24582008 ↗
  • Kahkoska AR, Shay CM, Crandell J, Dabelea D, Imperatore G, Lawrence JM, Liese AD, Pihoker C, Reboussin BA, Agarwal S, Tooze JA, Wagenknecht LE, Zhong VW, Mayer-Davis EJ. Association of Race and Ethnicity With Glycemic Control and Hemoglobin A1c Levels in Youth With Type 1 Diabetes. JAMA Netw Open. 2018 Sep 7;1(5):e181851. doi: 10.1001/jamanetworkopen.2018.1851. PubMed 30370425 ↗
  • Agarwal S, Hilliard M, Butler A. Disparities in Care Delivery and Outcomes in Young Adults With Diabetes. Curr Diab Rep. 2018 Jul 14;18(9):65. doi: 10.1007/s11892-018-1037-x. PubMed 30008025 ↗
  • Agarwal S, Kanapka LG, Raymond JK, Walker A, Gerard-Gonzalez A, Kruger D, Redondo MJ, Rickels MR, Shah VN, Butler A, Gonzalez J, Verdejo AS, Gal RL, Willi S, Long JA. Racial-Ethnic Inequity in Young Adults With Type 1 Diabetes. J Clin Endocrinol Metab. 2020 Aug 1;105(8):e2960-9. doi: 10.1210/clinem/dgaa236. PubMed 32382736 ↗
  • TODAY Study Group. Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and beta-cell function in TODAY. Diabetes Care. 2013 Jun;36(6):1749-57. doi: 10.2337/dc12-2393. PubMed 23704674 ↗
  • Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia. 2003 Jan;46(1):3-19. doi: 10.1007/s00125-002-1009-0. Epub 2003 Jan 11. PubMed 12637977 ↗
  • Gungor N, Arslanian S. Progressive beta cell failure in type 2 diabetes mellitus of youth. J Pediatr. 2004 May;144(5):656-9. doi: 10.1016/j.jpeds.2003.12.045. PubMed 15127006 ↗
  • Bacha F, Gungor N, Lee S, Arslanian SA. Progressive deterioration of beta-cell function in obese youth with type 2 diabetes. Pediatr Diabetes. 2013 Mar;14(2):106-11. doi: 10.1111/j.1399-5448.2012.00915.x. Epub 2012 Aug 23. PubMed 22913617 ↗
  • TODAY Study Group; Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, Arslanian S, Cuttler L, Nathan DM, Tollefsen S, Wilfley D, Kaufman F. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012 Jun 14;366(24):2247-56. doi: 10.1056/NEJMoa1109333. Epub 2012 Apr 29. PubMed 22540912 ↗
  • Song SH, Hardisty CA. Early onset type 2 diabetes mellitus: a harbinger for complications in later years--clinical observation from a secondary care cohort. QJM. 2009 Nov;102(11):799-806. doi: 10.1093/qjmed/hcp121. Epub 2009 Sep 4. PubMed 19734298 ↗
  • Sattar N, Rawshani A, Franzen S, Rawshani A, Svensson AM, Rosengren A, McGuire DK, Eliasson B, Gudbjornsdottir S. Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks. Circulation. 2019 May 7;139(19):2228-2237. doi: 10.1161/CIRCULATIONAHA.118.037885. PubMed 30955347 ↗
  • Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006 Dec 7;355(23):2427-43. doi: 10.1056/NEJMoa066224. Epub 2006 Dec 4. PubMed 17145742 ↗
  • Huo X, Gao L, Guo L, Xu W, Wang W, Zhi X, Li L, Ren Y, Qi X, Sun Z, Li W, Ji Q, Ran X, Su B, Hao C, Lu J, Guo X, Zhuo H, Zhang D, Pan C, Weng J, Hu D, Yang X, Ji L. Risk of non-fatal cardiovascular diseases in early-onset versus late-onset type 2 diabetes in China: a cross-sectional study. Lancet Diabetes Endocrinol. 2016 Feb;4(2):115-24. doi: 10.1016/S2213-8587(15)00508-2. Epub 2015 Dec 17. PubMed 26704379 ↗
  • Dart AB, Sellers EA, Martens PJ, Rigatto C, Brownell MD, Dean HJ. High burden of kidney disease in youth-onset type 2 diabetes. Diabetes Care. 2012 Jun;35(6):1265-71. doi: 10.2337/dc11-2312. Epub 2012 Mar 19. PubMed 22432116 ↗
  • Brown JB, Conner C, Nichols GA. Secondary failure of metformin monotherapy in clinical practice. Diabetes Care. 2010 Mar;33(3):501-6. doi: 10.2337/dc09-1749. Epub 2009 Dec 29. PubMed 20040656 ↗
  • TODAY Study Group; Bjornstad P, Drews KL, Caprio S, Gubitosi-Klug R, Nathan DM, Tesfaldet B, Tryggestad J, White NH, Zeitler P. Long-Term Complications in Youth-Onset Type 2 Diabetes. N Engl J Med. 2021 Jul 29;385(5):416-426. doi: 10.1056/NEJMoa2100165. PubMed 34320286 ↗
  • Kim JY, Goran MI, Toledo-Corral CM, Weigensberg MJ, Shaibi GQ. Comparing glycemic indicators of prediabetes: a prospective study of obese Latino Youth. Pediatr Diabetes. 2015 Dec;16(8):640-3. doi: 10.1111/pedi.12225. Epub 2014 Nov 11. PubMed 25385555 ↗
  • Lawrence JM, Mayer-Davis EJ, Reynolds K, Beyer J, Pettitt DJ, D'Agostino RB Jr, Marcovina SM, Imperatore G, Hamman RF; SEARCH for Diabetes in Youth Study Group. Diabetes in Hispanic American youth: prevalence, incidence, demographics, and clinical characteristics: the SEARCH for Diabetes in Youth Study. Diabetes Care. 2009 Mar;32 Suppl 2(Suppl 2):S123-32. doi: 10.2337/dc09-S204. PubMed 19246577 ↗
  • Bell RA, Mayer-Davis EJ, Beyer JW, D'Agostino RB Jr, Lawrence JM, Linder B, Liu LL, Marcovina SM, Rodriguez BL, Williams D, Dabelea D; SEARCH for Diabetes in Youth Study Group. Diabetes in non-Hispanic white youth: prevalence, incidence, and clinical characteristics: the SEARCH for Diabetes in Youth Study. Diabetes Care. 2009 Mar;32 Suppl 2(Suppl 2):S102-11. doi: 10.2337/dc09-S202. PubMed 19246575 ↗
  • Sargeant JA, Brady EM, Zaccardi F, Tippins F, Webb DR, Aroda VR, Gregg EW, Khunti K, Davies MJ. Adults with early-onset type 2 diabetes (aged 18-39 years) are severely underrepresented in diabetes clinical research trials. Diabetologia. 2020 Aug;63(8):1516-1520. doi: 10.1007/s00125-020-05174-9. Epub 2020 Jun 2. PubMed 32483683 ↗
  • Tonnies T, Brinks R, Isom S, Dabelea D, Divers J, Mayer-Davis EJ, Lawrence JM, Pihoker C, Dolan L, Liese AD, Saydah SH, D'Agostino RB, Hoyer A, Imperatore G. Projections of Type 1 and Type 2 Diabetes Burden in the U.S. Population Aged <20 Years Through 2060: The SEARCH for Diabetes in Youth Study. Diabetes Care. 2023 Feb 1;46(2):313-320. doi: 10.2337/dc22-0945. PubMed 36580405 ↗
  • Lawrence JM, Divers J, Isom S, Saydah S, Imperatore G, Pihoker C, Marcovina SM, Mayer-Davis EJ, Hamman RF, Dolan L, Dabelea D, Pettitt DJ, Liese AD; SEARCH for Diabetes in Youth Study Group. Trends in Prevalence of Type 1 and Type 2 Diabetes in Children and Adolescents in the US, 2001-2017. JAMA. 2021 Aug 24;326(8):717-727. doi: 10.1001/jama.2021.11165. PubMed 34427600 ↗
  • Xie J, Wang M, Long Z, Ning H, Li J, Cao Y, Liao Y, Liu G, Wang F, Pan A. Global burden of type 2 diabetes in adolescents and young adults, 1990-2019: systematic analysis of the Global Burden of Disease Study 2019. BMJ. 2022 Dec 7;379:e072385. doi: 10.1136/bmj-2022-072385. PubMed 36740855 ↗
  • Wu H, Patterson CC, Zhang X, Ghani RBA, Magliano DJ, Boyko EJ, Ogle GD, Luk AOY. Worldwide estimates of incidence of type 2 diabetes in children and adolescents in 2021. Diabetes Res Clin Pract. 2022 Mar;185:109785. doi: 10.1016/j.diabres.2022.109785. Epub 2022 Feb 18. PubMed 35189261 ↗
  • Perng W, Conway R, Mayer-Davis E, Dabelea D. Youth-Onset Type 2 Diabetes: The Epidemiology of an Awakening Epidemic. Diabetes Care. 2023 Mar 1;46(3):490-499. doi: 10.2337/dci22-0046. PubMed 36812420 ↗
  • Falkner B, Gidding S. Life-Course Implications of Pediatric Risk Factors for Cardiovascular Disease. Can J Cardiol. 2021 May;37(5):766-775. doi: 10.1016/j.cjca.2021.02.001. Epub 2021 Feb 11. PubMed 33581191 ↗
  • American Diabetes Association Professional Practice Committee. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2024. Diabetes Care. 2024 Jan 1;47(Suppl 1):S52-S76. doi: 10.2337/dc24-S004. PubMed 38078591 ↗
  • American Diabetes Association Professional Practice Committee. 14. Children and Adolescents: Standards of Care in Diabetes-2024. Diabetes Care. 2024 Jan 1;47(Suppl 1):S258-S281. doi: 10.2337/dc24-S014. PubMed 38078582 ↗
  • Misra A. Ethnic-Specific Criteria for Classification of Body Mass Index: A Perspective for Asian Indians and American Diabetes Association Position Statement. Diabetes Technol Ther. 2015 Sep;17(9):667-71. doi: 10.1089/dia.2015.0007. Epub 2015 Apr 22. PubMed 25902357 ↗
  • Florido R, Daya NR, Ndumele CE, Koton S, Russell SD, Prizment A, Blumenthal RS, Matsushita K, Mok Y, Felix AS, Coresh J, Joshu CE, Platz EA, Selvin E. Cardiovascular Disease Risk Among Cancer Survivors: The Atherosclerosis Risk In Communities (ARIC) Study. J Am Coll Cardiol. 2022 Jul 5;80(1):22-32. doi: 10.1016/j.jacc.2022.04.042. PubMed 35772913 ↗
  • Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007 Jul;92(7):2506-12. doi: 10.1210/jc.2006-2190. Epub 2007 Apr 24. PubMed 17456578 ↗
  • Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, Butt AA, Bidwell Goetz M, Leaf D, Oursler KA, Rimland D, Rodriguez Barradas M, Brown S, Gibert C, McGinnis K, Crothers K, Sico J, Crane H, Warner A, Gottlieb S, Gottdiener J, Tracy RP, Budoff M, Watson C, Armah KA, Doebler D, Bryant K, Justice AC. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013 Apr 22;173(8):614-22. doi: 10.1001/jamainternmed.2013.3728. PubMed 23459863 ↗
  • Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, Robinson KA, Sabadosa KA, Stecenko A, Slovis B; CFRD Guidelines Committee. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010 Dec;33(12):2697-708. doi: 10.2337/dc10-1768. No abstract available. PubMed 21115772 ↗
  • Frost F, Nazareth D, Fauchier L, Wat D, Shelley J, Austin P, Walshaw MJ, Lip GYH. Prevalence, risk factors and outcomes of cardiac disease in cystic fibrosis: a multinational retrospective cohort study. Eur Respir J. 2023 Oct 26;62(4):2300174. doi: 10.1183/13993003.00174-2023. Print 2023 Oct. PubMed 37474158 ↗
  • Sandouk Z, Nachawi N, Simon R, Wyckoff J, Putman MS, Kiel S, Soltman S, Moran A, Moheet A. Coronary artery disease in patients with cystic fibrosis - A case series and review of the literature. J Clin Transl Endocrinol. 2022 Oct 5;30:100308. doi: 10.1016/j.jcte.2022.100308. eCollection 2022 Dec. PubMed 36267108 ↗
  • Roberts R, Speight L, Lee J, George L, Ketchell RI, Lau D, Duckers J. Retinal screening of patients with cystic fibrosis-related diabetes in Wales -- a real eye opener. J Cyst Fibros. 2015 Mar;14(2):282-4. doi: 10.1016/j.jcf.2014.07.014. Epub 2014 Sep 13. PubMed 25224328 ↗
  • Lind-Ayres M, Thomas W, Holme B, Mauer M, Caramori ML, Moran A. Microalbuminuria in patients with cystic fibrosis. Diabetes Care. 2011 Jul;34(7):1526-8. doi: 10.2337/dc10-2231. Epub 2011 May 11. PubMed 21562324 ↗
  • Schwarzenberg SJ, Thomas W, Olsen TW, Grover T, Walk D, Milla C, Moran A. Microvascular complications in cystic fibrosis-related diabetes. Diabetes Care. 2007 May;30(5):1056-61. doi: 10.2337/dc06-1576. Epub 2007 Feb 23. PubMed 17322485 ↗
  • Colomba J, Boudreau V, Lehoux-Dubois C, Desjardins K, Coriati A, Tremblay F, Rabasa-Lhoret R. The main mechanism associated with progression of glucose intolerance in older patients with cystic fibrosis is insulin resistance and not reduced insulin secretion capacity. J Cyst Fibros. 2019 Jul;18(4):551-556. doi: 10.1016/j.jcf.2019.01.009. Epub 2019 Jan 30. PubMed 30711385 ↗
  • Blackman SM, Hsu S, Vanscoy LL, Collaco JM, Ritter SE, Naughton K, Cutting GR. Genetic modifiers play a substantial role in diabetes complicating cystic fibrosis. J Clin Endocrinol Metab. 2009 Apr;94(4):1302-9. doi: 10.1210/jc.2008-2186. Epub 2009 Jan 6. PubMed 19126627 ↗
  • Blackman SM, Hsu S, Ritter SE, Naughton KM, Wright FA, Drumm ML, Knowles MR, Cutting GR. A susceptibility gene for type 2 diabetes confers substantial risk for diabetes complicating cystic fibrosis. Diabetologia. 2009 Sep;52(9):1858-65. doi: 10.1007/s00125-009-1436-2. Epub 2009 Jul 8. PubMed 19585101 ↗
  • Blackman SM, Commander CW, Watson C, Arcara KM, Strug LJ, Stonebraker JR, Wright FA, Rommens JM, Sun L, Pace RG, Norris SA, Durie PR, Drumm ML, Knowles MR, Cutting GR. Genetic modifiers of cystic fibrosis-related diabetes. Diabetes. 2013 Oct;62(10):3627-35. doi: 10.2337/db13-0510. Epub 2013 May 13. PubMed 23670970 ↗
  • Aksit MA, Pace RG, Vecchio-Pagan B, Ling H, Rommens JM, Boelle PY, Guillot L, Raraigh KS, Pugh E, Zhang P, Strug LJ, Drumm ML, Knowles MR, Cutting GR, Corvol H, Blackman SM. Genetic Modifiers of Cystic Fibrosis-Related Diabetes Have Extensive Overlap With Type 2 Diabetes and Related Traits. J Clin Endocrinol Metab. 2020 May 1;105(5):1401-15. doi: 10.1210/clinem/dgz102. PubMed 31697830 ↗
  • Malik SS, Padmanabhan D, Hull-Meichle RL. Pancreas and islet morphology in cystic fibrosis: clues to the etiology of cystic fibrosis-related diabetes. Front Endocrinol (Lausanne). 2023 Nov 23;14:1269139. doi: 10.3389/fendo.2023.1269139. eCollection 2023. PubMed 38075070 ↗
  • Norris AW, Ode KL, Merjaneh L, Sanda S, Yi Y, Sun X, Engelhardt JF, Hull RL. Survival in a bad neighborhood: pancreatic islets in cystic fibrosis. J Endocrinol. 2019 Apr;241(1):R35-R50. doi: 10.1530/JOE-18-0468. PubMed 30759072 ↗
  • Sheikh S, Gudipaty L, De Leon DD, Hadjiliadis D, Kubrak C, Rosenfeld NK, Nyirjesy SC, Peleckis AJ, Malik S, Stefanovski D, Cuchel M, Rubenstein RC, Kelly A, Rickels MR. Reduced beta-Cell Secretory Capacity in Pancreatic-Insufficient, but Not Pancreatic-Sufficient, Cystic Fibrosis Despite Normal Glucose Tolerance. Diabetes. 2017 Jan;66(1):134-144. doi: 10.2337/db16-0394. Epub 2016 Aug 5. PubMed 27495225 ↗
  • Nyirjesy SC, Sheikh S, Hadjiliadis D, De Leon DD, Peleckis AJ, Eiel JN, Kubrak C, Stefanovski D, Rubenstein RC, Rickels MR, Kelly A. beta-Cell secretory defects are present in pancreatic insufficient cystic fibrosis with 1-hour oral glucose tolerance test glucose >/=155 mg/dL. Pediatr Diabetes. 2018 Nov;19(7):1173-1182. doi: 10.1111/pedi.12700. Epub 2018 Jun 21. PubMed 29885044 ↗
  • Moheet A, Moran A. New Concepts in the Pathogenesis of Cystic Fibrosis-Related Diabetes. J Clin Endocrinol Metab. 2022 May 17;107(6):1503-1509. doi: 10.1210/clinem/dgac020. PubMed 35106591 ↗
  • Szentpetery S, Fernandez GS, Schechter MS, Jain R, Flume PA, Fink AK. Obesity in Cystic fibrosis: prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registry. J Cyst Fibros. 2022 Sep;21(5):777-783. doi: 10.1016/j.jcf.2022.03.010. Epub 2022 Apr 5. PubMed 35396178 ↗
  • Harindhanavudhi T, Wang Q, Dunitz J, Moran A, Moheet A. Prevalence and factors associated with overweight and obesity in adults with cystic fibrosis: A single-center analysis. J Cyst Fibros. 2020 Jan;19(1):139-145. doi: 10.1016/j.jcf.2019.10.004. Epub 2019 Nov 11. PubMed 31727452 ↗
  • Sawicki GS, McKone EF, Pasta DJ, Millar SJ, Wagener JS, Johnson CA, Konstan MW. Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data. Am J Respir Crit Care Med. 2015 Oct 1;192(7):836-42. doi: 10.1164/rccm.201503-0578OC. PubMed 26132840 ↗
  • Rowe SM, McColley SA, Rietschel E, Li X, Bell SC, Konstan MW, Marigowda G, Waltz D, Boyle MP; VX09-809-102 Study Group. Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR. Ann Am Thorac Soc. 2017 Feb;14(2):213-219. doi: 10.1513/AnnalsATS.201609-689OC. PubMed 27898234 ↗
  • Rowe SM, Daines C, Ringshausen FC, Kerem E, Wilson J, Tullis E, Nair N, Simard C, Han L, Ingenito EP, McKee C, Lekstrom-Himes J, Davies JC. Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis. N Engl J Med. 2017 Nov 23;377(21):2024-2035. doi: 10.1056/NEJMoa1709847. Epub 2017 Nov 3. PubMed 29099333 ↗
  • Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordonez C, Elborn JS; VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011 Nov 3;365(18):1663-72. doi: 10.1056/NEJMoa1105185. PubMed 22047557 ↗
  • Nichols DP, Paynter AC, Heltshe SL, Donaldson SH, Frederick CA, Freedman SD, Gelfond D, Hoffman LR, Kelly A, Narkewicz MR, Pittman JE, Ratjen F, Rosenfeld M, Sagel SD, Schwarzenberg SJ, Singh PK, Solomon GM, Stalvey MS, Clancy JP, Kirby S, Van Dalfsen JM, Kloster MH, Rowe SM; PROMISE Study group. Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial. Am J Respir Crit Care Med. 2022 Mar 1;205(5):529-539. doi: 10.1164/rccm.202108-1986OC. PubMed 34784492 ↗
  • Middleton PG, Mall MA, Drevinek P, Lands LC, McKone EF, Polineni D, Ramsey BW, Taylor-Cousar JL, Tullis E, Vermeulen F, Marigowda G, McKee CM, Moskowitz SM, Nair N, Savage J, Simard C, Tian S, Waltz D, Xuan F, Rowe SM, Jain R; VX17-445-102 Study Group. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31. PubMed 31697873 ↗
  • Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, Mall MA, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, Taylor-Cousar JL, McCoy KS; VX17-445-103 Trial Group. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31. PubMed 31679946 ↗
  • Davies JC, Wainwright CE, Canny GJ, Chilvers MA, Howenstine MS, Munck A, Mainz JG, Rodriguez S, Li H, Yen K, Ordonez CL, Ahrens R; VX08-770-103 (ENVISION) Study Group. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med. 2013 Jun 1;187(11):1219-25. doi: 10.1164/rccm.201301-0153OC. PubMed 23590265 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Nov 2028, 38 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2025
First posted
Feb 20, 2025
StartActual
Sep 18, 2025
Primary completionEst.
Nov 30, 2028
CompletionEst.
Nov 30, 2028
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06837181
Collaborators
Cystic Fibrosis Foundation
Responsible party
Sponsor
First posted
Feb 20, 2025
Start date
Sep 18, 2025
Primary completion
Nov 30, 2028 (estimated)
Completion
Nov 30, 2028 (estimated)
Last update
Feb 10, 2026

Study contacts

Judy Sibayan, MPH, CCRP
Contact
jsibayan@jaeb.org
813-975-8690
Haley Fonseca, PhD, RDN, LDN
Contact
hfonseca@jaeb.org
813-975-8690

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion